Anika Therapeutics | ANIK - Selling And Administration Expenses


Anika Therapeutics reported $10.01M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 4.27B 669M Sep/2026
Agenus USD 6.21M 4.34M Mar/2026
Agios Pharmaceuticals USD 51.55M 13.09M Jun/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.63M 4.88M Jun/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Halozyme Therapeutics USD 58.24M 1.24M Sep/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 253.03M 5.56M Sep/2026
Integra LifeSciences USD 161.02M 5.2M Sep/2026
Intrexon USD 10.31M 41K Jun/2024
J&J USD 6.25B 168M Sep/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Ligand Pharmaceuticals USD 72.62M 43.49M Sep/2026
MacroGenics USD 7.9M 1.81M Jun/2026
Merit Medical Systems USD 129.23M 18.76M Jun/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.31B 325M Sep/2026
Smith & Nephew USD 1.45B 29M Jun/2026
Stryker USD 2.12B 32M Jun/2026
Veracyte USD 57.95M 2.25M Sep/2026
Xencor USD 71.93M 5.61M Sep/2026
Zimmer Biomet Holdings USD 855M 56.6M Sep/2026